Looking at the universe of stocks we cover at Dividend Channel, on 7/1/13, American Strategic Income Portfolio III (CSP will trade ex-dividend, for its monthly dividend of $0.0425, payable on 7/17/13. As a percentage of CSP's recent stock price of $6.90, this dividend works out to approximately 0.62%, so look for shares of American Strategic Income Portfolio III to trade 0.62% lower — all else being equal — when CSP shares open for trading on 7/1/13.Below is a dividend history chart for CSP, showing historical dividends prior to the most recent $0.0425 declared by American Strategic Income Portfolio III: In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from CSP is likely to continue, and whether the current estimated yield of 7.39% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of CSP shares, versus its 200 day moving average: Looking at the chart above, CSP's low point in its 52 week range is $6.68 per share, with $7.72 as the 52 week high point — that compares with a last trade of $6.90. In Friday trading, American Strategic Income Portfolio III shares are currently up about 0.4% on the day.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
Tesla Puts Out Fire in China as Production Plant Gets Under Way
China is the second-largest market globally for Tesla.
Pinterest and Zoom Sputter on Second Day of Trading
Shares of last week's IPO darlings Pinterest and Zoom both fall on their second day of trading as investors digest both companies' longer-term prospects.
A Tough Week for Biotech, the Candidates' Whipping Boy Again
Talk among a mammoth field of presidential candidates about drug price controls and an expansion of Medicare isn't helping biotech and health care stocks.